Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms P95HER2-T cell bispecific antibody (Roche) |
Target |
Mechanism CD3ε inhibitors(CD3e molecule inhibitors), p95HER2 inhibitors(HER2/neu-p95 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Breast Cancer | Preclinical | - | 03 Oct 2018 | |
HER2 Positive Breast Cancer | Preclinical | - | 03 Oct 2018 |